Seaport Therapeutics Sets January 12 Presentation at J.P. Morgan Healthcare Conference

Edgen Stock·Jan 05 2026, 18:21

Share to

Share to

Copy link

Key Takeaways

Seaport Therapeutics, a clinical-stage company specializing in neuropsychiatric drugs, has scheduled a presentation at the upcoming 44th Annual J.P. Morgan Healthcare Conference. The event will feature CEO Daphne Zohar and will spotlight the company's proprietary Glyph technology platform, designed to improve drug delivery and safety.

Presentation Scheduled: Seaport Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 9:30 a.m. UTC-8.
Key Leadership: CEO Daphne Zohar will lead the presentation, with Co-founder Dr. Steve Paul and Chief Scientific Officer Dr. Michael Chen joining for the Q&A session.
Proprietary Technology: The company's pipeline is based on its Glyph platform, which aims to enhance oral bioavailability and reduce side effects for neuropsychiatric medicines.

Seaport Therapeutics to Present at J.P. Morgan Conference on January 12

Clinical-stage Seaport Therapeutics announced on January 5, 2026, that its leadership will present at the 44th Annual J.P. Morgan Healthcare Conference. Co-Founder and Chief Executive Officer Daphne Zohar is scheduled to present on Monday, January 12, 2026, at 9:30 a.m. UTC-8. The presentation provides a significant platform for the private company to detail its strategy and pipeline to investors and industry peers.

Following the main presentation, Ms. Zohar will be joined for a question-and-answer session by the company's other co-founders, Chair Steve Paul, M.D., and Chief Scientific Officer Michael Chen, Ph.D. The inclusion of the core scientific team signals a likely focus on the technical and clinical aspects of Seaport's therapeutic candidates.

Glyph Platform Aims to Overcome Drug Delivery Hurdles

Seaport Therapeutics centers its development efforts on novel neuropsychiatric medicines for conditions with high unmet patient needs. The company's entire pipeline is built upon its proprietary Glyph technology platform. This platform is specifically engineered to improve how drugs are processed by the body.

The key objectives of the Glyph technology are to enable oral bioavailability, bypass first-pass metabolism in the liver, and reduce the risk of liver enzyme elevations or hepatotoxicity. By overcoming these common limitations, Seaport aims to advance clinically validated mechanisms that were previously hindered by delivery and side-effect challenges, potentially unlocking new first-in-class and best-in-class medicines.